Drug Trial Radar · NCT06665256
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
21
Actual
Start
Dec 17, 2024
Primary completion
Mar 9, 2029
Study completion Nov 29, 2032
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies (IIM)
Conditions
- Idiopathic Inflammatory Myopathies
Interventions
Rapcabtagene autoleucelBiological
Single infusion of rapcabtagene autoleucel after lymphodepleting therapy with fludarabine (adjusted based on renal impairment) and cyclophosphamide daily for 3 days.
Active Comparator OptionOther
Investigator choice of treatment as per protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving moderate- to-major improvement in Total Improvement Score (TIS) at Week 52Time frame: Week 52
Locations
68 sites in 15 countries. Site status is shown where the registry gives one.
University Of Alabama
Birmingham, Alabama
FL Medical Clinic Orlando Health
Zephyrhills, Florida
Augusta University Georgia
Augusta, Georgia
Northwestern University
Chicago, Illinois
University Of Iowa
Iowa City, Iowa
Duke Clinical Research Institute
Durham, North Carolina
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Baylor University Medical Center
Dallas, Texas
Houston Methodist Hospital
Houston, Texas
LDS Hospital
Salt Lake City, Utah
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Barretos, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Brest, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Rennes, France
Novartis Investigative Site
Aachen, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Mainz, Germany
Novartis Investigative Site
Nuremberg, Germany
Novartis Investigative Site
Ulm, Germany
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site
Leipzig, Saxony, Germany
Novartis Investigative Site
Jena, Thuringia, Germany
Novartis Investigative Site
Haifa, Israel
Novartis Investigative Site
Ramat Gan, Israel
Novartis Investigative Site
Tel Aviv, Israel
Novartis Investigative Site
Ancona, AN, Italy
Novartis Investigative Site
Brescia, BS, Italy
Novartis Investigative Site
Monza, MB, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Rozzano, MI, Italy
Novartis Investigative Site
Verona, VR, Italy
Novartis Investigative Site
Fukuoka, Japan
Novartis Investigative Site
Ishikawa, Japan
Novartis Investigative Site
Kyoto, Japan
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.